Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
alector
Overview
Alector, Inc. is a clinical-stage biotechnology company pioneering immuno-neurology to treat neurodegenerative diseases, including Alzheimer's and Parkinson's. By targeting the brain's immune system, Alector aims to develop therapies that address the underlying causes of these debilitating conditions, rather than solely managing symptoms. The company focuses on discovering and developing novel treatments that modulate immune cell activity within the brain to promote neuronal repair and prevent further neurodegeneration, positioning itself as a leader in this emerging therapeutic area. Alector operates within the highly competitive biopharmaceutical industry, specifically targeting the underserved and rapidly growing market for neurodegenerative disease treatments.
alector's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 5 |
Consulting | 1 |
Service | 2 |
Design | 0 |
Education | 0 |
Finance | 7 |
Management | 10 |
Hr | 7 |
Legal | 7 |
Marketing | 2 |
Medical | 22 |
Operations | 13 |
Department | 31 |
Product | 0 |
Management | 2 |
Estate | 0 |
Research | 55 |
Sales | 0 |
Technical | 6 |
Trades | 0 |
Alector's department distribution reveals a distinct R&D-centric organizational structure characteristic of a clinical-stage biotechnology company heavily invested in scientific innovation. The significant concentration of employees in Research (55) and Medical (22), encompassing over 34% of the workforce, underscores their dedication to advancing immuno-neurology and developing novel therapeutics. Supporting functions such as General Management (10), Finance (7), HR (7), Legal (7), and Operations (13) suggest a robust infrastructure capable of managing complex research and clinical trials. The lean Sales (0) and Marketing (2) teams suggest Alector is currently prioritizing research, clinical development, and regulatory approvals, indicating they are likely pre-commercialization or in early-stage commercialization with a focus on strategic partnerships. The 'Other Department' headcount of 31, almost 14% of the workforce, indicates a need for greater functional granularity and specialization as the company scales. The relatively low number in Technical (6) suggests potential outsourcing of manufacturing or reliance on strategic partnerships. Overall, the organizational chart reflects a company prioritizing innovation and clinical validation over immediate commercial pursuits, which is typical for a biotechnology firm in its developmental stage.
alector's employees by locations
Employee Count by Country
Total: 170 employees
Alector's workforce is overwhelmingly concentrated in the United States (166 employees), indicating that the company's core research and development operations, as well as likely its executive leadership and administrative functions, are based there. This centralization aligns with the company's need to be close to key resources, including leading research institutions, prominent talent pools, and venture capital funding centers, all of which are heavily concentrated in the US biotechnology ecosystem. The small presence in the United Kingdom (1) and Portugal (1) hints at early-stage collaborations or potential market exploration in Europe, potentially due to access to specific expertise or clinical trial opportunities. The presence of two employees in Argentina might suggest outsourced functions, remote workers, or potential partnerships with Latin American research institutions. The highly centralized workforce, predominantly within the US, is a strategic decision reflecting Alector's current stage of development as an innovation-driven biotechnology company. As Alector advances its pipeline and moves closer to commercialization, a more distributed workforce strategy, with increased presence in key European and potentially Asian markets, would be anticipated to support regulatory submissions, market access, and commercial operations.
Want to stay ahead of alector's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early